Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT03915678 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Atezolizumab Combined With BDB001 AnD Immunogenic Radiotherapy in Patients With Advanced Solid Tumors

Study acronym: AGADIR
StatusActive, Not Recruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Trial status changed: Recruiting → Active, Not Recruiting
    • Site details revised at 11 of 11 sites
    v12
  2. Primary completion date: Sep 2024 to Dec 2026
    • Study completion date: Mar 2026 to Dec 2027
    v11
  3. Collaborators revised (3)v10
  4. Primary completion date: Sep 2023 to Sep 2024
    • Study completion date: Mar 2025 to Mar 2026
    • Eligibility criteria expanded, about 21 words
    • Site details revised at 2 of 11 sites
    v9
  5. Site details revised at 1 of 11 sitesv8
Show 6 earlier versionsHide 6 earlier versions
  1. Eligibility criteria expanded, about 46 words
    • Study sites revised (11)
    v7
  2. Site details revised at 3 of 11 sitesv6
  3. Study sites: 10 to 11
    • Eligibility criteria expanded, about 7 words
    • Study description shortened, about 2 words
    v5
  4. Trial status: Not Yet Recruiting to Recruiting
    • Start date changed from estimate of Mar 2021 to Mar 31, 2021
    • Site details revised at 10 of 10 sites
    v4
  5. Primary completion date: Jul 2023 to Sep 2023
    • Study completion date: Jan 2025 to Mar 2025
    • Start date: Jan 2021 to Mar 2021
    • Eligibility criteria expanded, about 94 words
    v3
  6. Primary completion date: Nov 2021 to Jul 2023v2 Show 9 more changesShow less
    • Start date: Jun 2019 to Jan 2021
    • Primary endpoints: 1 to 6
    • Study completion date: Jun 2023 to Jan 2025
    • Interventions: Association atezolizumab + G100 + RT (Drug), Association atezolizumab + G100 + RT (Drug), Association atezolizumab + G100 + RT (Drug)… to Association atezolizumab + BDB001 + RT (Drug), Association atezolizumab + BDB001 + RT (Drug), Association atezolizumab + BDB001 + RT…
    • Eligibility criteria shortened, about 644 words
    • Secondary endpoints: 12 to 17
    • Collaborators revised (3)
    • Study description expanded, about 5 words
    • Study title shortened, about 1 word
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Institut Bergonié
40 trials monitored
See 1 trial at risk
Breast Cancer
5,418 trials monitored
See 296 trials at risk
Lung Cancer
4,790 trials monitored
See 263 trials at risk
Non-Small Cell Lung Cancer (NSCLC)
3,078 trials monitored
See 172 trials at risk
and 4 more diseases
Basket trial concept to independently and simultaneously assess the effects of the association of atezolizumab + BDB001 + radiotherapy in multiple solid tumors.
Trial Details
NCT Number NCT03915678
Lead Sponsor Institut Bergonié
Collaborators: Roche Pharma AG, National Cancer Institute, France, Eikon Therapeutics
Conditions
(from sponsor)		 Solid Tumor, Adult, Pancreatic Cancer, Virus-associated Tumors, Non Small Cell Lung Cancer, Melanoma, Bladder Cancer, Triple Negative Breast Cancer
Related terms Carcinoma, Non-Small-Cell Lung, Melanoma, Neoplasm Metastasis, Neoplasms, Pancreatic Neoplasms, Triple Negative Breast Neoplasms, Urinary Bladder Neoplasms
Enrollment 247 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov